Peroxisome Proliferator-activated Receptor γ Induces a Phenotypic Switch from Activated to Quiescent Hepatic Stellate Cells
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Depletion of peroxisome proliferator-activated receptor gamma (PPARgamma) accompanies myofibroblastic transdifferentiation of hepatic stellate cells (HSC), the primary cellular event underlying liver fibrogenesis. The treatment of activated HSC in vitro or in vivo with synthetic PPARgamma ligands suppresses the fibrogenic activity of HSC. However, it is uncertain whether PPARgamma is indeed a molecular target of this effect, because the ligands are also known to have receptor-independent actions. To test this question, the present study examined the effects of forced expression of PPARgamma via an adenoviral vector on morphologic and biochemical features of culture-activated HSC. The vector-mediated expression of PPARgamma itself is sufficient to reverse the morphology of activated HSC to the quiescent phenotype with retracted cytoplasm, prominent dendritic processes, reduced stress fibers, and accumulation of retinyl palmitate. These effects are abrogated by concomitant expression of a dominant negative mutant of PPARgamma that prevents transactivation of but not binding to the PPAR response element. PPARgamma expression also inhibits the activation markers such as the expression of alpha-smooth muscle actin, type I collagen, and transforming growth factor beta1; DNA synthesis; and JunD binding to the activator protein-1 (AP-1) site and AP-1 promoter activity. Inhibited JunD activity by PPARgamma is not due to reduced JunD expression or JNK activity or to a competition for p300. But it is due to a JunD-PPARgamma interaction as demonstrated by co-immunoprecipitation and glutathione S-transferase pull-down analysis. Further, the use of deletion constructs reveals that the DNA binding region of PPARgamma is the JunD interaction domain. In summary, our results demonstrate that the restoration of PPARgamma reverses the activated HSC to the quiescent phenotype and suppresses AP-1 activity via a physical interaction between PPARgamma and JunD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“HSC activation is therefore associated with low levels of PPAR-γ expression, and the assumed relation between PPAR-γ and liver fibrosis was confirmed in an experimental restoration of PPAR-γ levels in HSCs, which resulted in a regression of aHSCs to quiescence state.[126,127]”
From Nuclear receptors in liver fibrosis (2021) · cites this paper as [127]
Citations
Cites
1 retracted
Cytokines suppress adipogenesis and PPAR-γ function through the TAK1/TAB1/NIK cascade
Suzawa, M., Takada, I., Yanagisawa, J., Ohtake, F., Ogawa, S., Yamauchi, T., Kadowaki, T., Takeuchi, Y., Shibuya, H., Gotoh, Y., et al. (2003) · Nature Cell Biology · doi:10.1038/ncb942 · Cited by 292
RetractedAdipogenesis and Obesity: Rounding Out the Big Picture
Spiegelman, B. M., & Flier, J. S. (1996) · Cell · doi:10.1016/s0092-8674(00)81359-8 · Cited by 1,269
Chawla, A., Barak, Y., Nagy, L., Liao, D., Tontonoz, P., & Evans, R. M. (2001) · Nature Medicine · doi:10.1038/83336 · Cited by 1,069
15-Deoxy-Δ 12,14 -prostaglandin J 2 inhibits multiple steps in the NF-κB signaling pathway
Straus, D. S., Pascual, G., Li, M., Welch, J. S., Ricote, M., Hsiang, C.-H., Sengchanthalangsy, L. L., Ghosh, G., & Glass, C. K. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.9.4844 · Cited by 1,004
Peroxisome proliferator-activated receptors and hepatic stellate cell activation
Miyahara, T., Schrum, L., Rippe, R., Xiong, S., Yee, H. F., Motomura, K., Anania, F. A., Willson, T. M., & Tsukamoto, H. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m006577200 · Cited by 473
Self-citationGalli, A., Crabb, D. W., Ceni, E., Salzano, R., Mello, T., Svegliati–Baroni, G., Ridolfi, F., Trozzi, L., Surrenti, C., & Casini, A. (2002) · Gastroenterology · doi:10.1053/gast.2002.33666 · Cited by 440
Bissell, D. M., Wang, S. S., Jarnagin, W. R., & Roll, F. J. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118055 · Cited by 419
Marra, F., Efsen, E., Romanelli, R. G., Caligiuri, A., Pastacaldi, S., Batignani, G., Bonacchi, A., Caporale, R., Laffi, G., Pinzani, M., et al. (2000) · Gastroenterology · doi:10.1053/gast.2000.9365 · Cited by 409
Janknecht, R., & Hunter, T. (1996) · Nature · doi:10.1038/383022a0 · Cited by 393
Saxena, N. K., Ikeda, K., Rockey, D. C., Friedman, S. L., & Anania, F. A. (2002) · Hepatology · doi:10.1053/jhep.2002.32029 · Cited by 382
Research works printed but not linked: 8
- Kojima, 2000, Blood, 95, 1309
- Buck, 2000, Am. J. Physiol., 278, G321
- Hellerbrand, 1998, Am. J. Physiol., 275, G269
- Tsukamoto, 1996, Am. J. Physiol., 270, G581
- Xiong, 2001, Hepatology, 34, 520A
- Friedman, 1993, Am. J. Physiol., 264, G947
- Gressner, 1996, Kidney Int. Suppl., 54, S39
- Salbert, 1993, Mol. Endocrinol., 7, 1347
Cited by
Items 101–200 of 327
Novel Molecular Mechanisms in the Development of Non-Alcoholic Steatohepatitis
Povero, D., & Feldstein, A. E. (2016) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2016.40.1.1 · Cited by 60
Jaster, R., Lichte, P., Fitzner, B., Brock, P., Glass, A. S., Karopka, T., Gierl, L., Koczan, D., Thiesen, H., Sparmann, G. H., et al. (2005) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2005.tb00497.x · Cited by 64
Fan, J., Li, X., Li, P., Li, N., Wang, T., Shen, H., Siow, Y. L., Choy, P. C., & Gong, Y. (2007) · Biochemistry and Cell Biology · doi:10.1139/o07-010 · Cited by 59
“The activation of HSCs could be initiated by the stimulation of cytokines, oxidative stress, and the deposition of degraded ECM (Pinzani and Marra 2001).”
BackgroundInfluentialEpigenetic cell fate regulation of hepatic stellate cells
Tsukamoto, H., Zhu, N., Asahina, K., Mann, D. A., & Mann, J. (2011) · Hepatology Research · doi:10.1111/j.1872-034x.2011.00804.x · Cited by 57
Self-citationAtta, H. M., Elrehany, M. A., Hammam, O. A., Abdelghany, H. M., Ramzy, M. M., Roderfeld, M., Roeb, E., Al-Hendy, A., Abdelraheim, S. R., Allam, H. H., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0112384 · Cited by 57
Hernández‐Aquino, E., Quezada‐Ramírez, M. A., Silva-Olivares, A., Casas‐Grajales, S., Ramos‐Tovar, E., Flores‐Beltrán, R. E., Segovia, J., Shibayama, M., & Muriel, P. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172730 · Cited by 60
Clinical application of transcriptional activators of bile salt transporters
Baghdasaryan, A., Chiba, P., & Trauner, M. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2013.12.001 · Cited by 60
Ringseis, R., Müller, A., Herter, C., Gahler, S., Steinhart, H., & Eder, K. (2005) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2005.12.002 · Cited by 67
Vitamin A and insulin are required for the maintenance of hepatic stellate cell quiescence
Yoneda, A., Sakai, K., Niitsu, Y., & Tamura, Y. (2016) · Experimental Cell Research · doi:10.1016/j.yexcr.2016.01.012 · Cited by 63
Zhao, H., Wang, Z., Tang, F., Zhao, Y., Feng, D., Li, Y., Hu, Y. W., Wang, C., Zhou, J., Tian, X., et al. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.10.013 · Cited by 56
Zhai, X., Qiao, H., Guan, W., Li, Z., Cheng, Y., Jia, X., & Zhou, Y. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.10.055 · Cited by 57
Zhu, N., Wang, J., & Tsukamoto, H. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.156703 · Cited by 55
Self-citationSalunkhe, S. A., Chitkara, D., Mahato, R. I., & Mittal, A. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.04.003 · Cited by 57
Peroxisome proliferator-activated receptor gamma inhibits hepatic fibrosis in rats
Wang, Z., Xu, J.-P., Zheng, Y.-C., Chen, W., Sun, Y.-W., Wu, Z.-Y., & Luo, M. (2011) · Hepatobiliary & pancreatic diseases international · doi:10.1016/s1499-3872(11)60009-x · Cited by 58
Schistosoma mansoni: Egg-induced downregulation of hepatic stellate cell activation and fibrogenesis
Anthony, B. J., Mathieson, W., Castro‐Borges, W., & Allen, J. (2010) · Experimental Parasitology · doi:10.1016/j.exppara.2009.12.009 · Cited by 55
“Depletion of PPARc is associated with HSC activation whereas increasing PPARc expression induces HSC quiescence and has been found to inhibit activation markers such as aSMA and collagen (Hazra et al., 2004).”
BackgroundWnt/beta‐catenin signaling and its modulators in nonalcoholic fatty liver diseases
Harini, K. S., & Ezhilarasan, D. (2022) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2022.10.003 · Cited by 57
Akahori, T., Sho, M., Hamada, K., Suzaki, Y., Kuzumoto, Y., Nomi, T., Nakamura, S., Enomoto, K., Kanehiro, H., & Nakajima, Y. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2007.07.030 · Cited by 58
Leptin inhibits PPARγ gene expression in hepatic stellate cells in the mouse model of liver damage
Zhou, Y., Jia, X., Qin, J., Lu, C., Zhu, H., Li, X., Han, X., & Sun, X. (2010) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2010.03.005 · Cited by 55
Zhu, W., Tang, C., Xiao, Z., Zhu, J.-N., Lin, Q., Fu, Y., Hu, Z.-Q., Zhang, Z., Yang, M., Zheng, X., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13048 · Cited by 53
Mollica, G., Senesi, P., Codella, R., Vacante, F., Montesano, A., Luzi, L., & Terruzzi, I. (2019) · Digestive and Liver Disease · doi:10.1016/j.dld.2019.09.002 · Cited by 53
Nonalcoholic Fatty Liver Disease
Sanyal, A. J. (2004) · Clinics in Liver Disease · doi:10.1016/j.cld.2004.04.014 · Cited by 54
Smart, D. E., Green, K., Oakley, F., Weitzman, J. B., Yaniv, M., Reynolds, G., Mann, J., Millward-Sadler, H., & Mann, D. A. (2006) · Hepatology · doi:10.1002/hep.21436 · Cited by 52
Effectiveness of the PPARγ agonist, GW570, in liver fibrosis
Yang, L., Stimpson, S. A., Chen, L., Harrington, W. W., & Rockey, D. C. (2010) · Inflammation Research · doi:10.1007/s00011-010-0226-0 · Cited by 57
Qian, J., Niu, M., Zhai, X., Zhou, Q., & Zhou, Y. (2012) · Pharmacological Research · doi:10.1016/j.phrs.2012.06.003 · Cited by 51
Zhou, Y., Jia, X., Wang, G., Wang, X., & Liu, J. (2009) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-009-0027-3 · Cited by 54
“AKT and ERK are the major kinases responsible for cell proliferation, differentiation and survival [2, 25‐28], and the transcription factor PPARc affects the transdifferentiation and proliferation of HSCs [16, 17 , 19].”
BackgroundResultInfluentialTsolaki, E., Athanasiou, E., Gounari, E., Ζώγας, Ν., Siotou, E., Yiangou, M., Anagnostopoulos, Α., & Yannaki, E. (2014) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2014.05.003 · Cited by 51
Expression of carboxylesterase and lipase genes in rat liver cell-types
Mello, T., Nakatsuka, A., Fears, S., Davis, W., Tsukamoto, H., Bosron, W. F., & Sanghani, S. P. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.07.024 · Cited by 50
Self-citationJin, H., Yamamoto, N., Uchida, K., Terai, S., & Sakaida, I. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.10.083 · Cited by 50
Jiang, Y., Wang, S., Zhao, Y., Lin, C., Zhong, F., Jin, L., He, F., & Wang, H. (2015) · The FASEB Journal · doi:10.1096/fj.14-251751 · Cited by 48
Mannaerts, I., Schroyen, B., Verhulst, S., Lommel, L. V., Schuit, F. C., Nyssen, M., & van Grunsven, L. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0084071 · Cited by 53
“Upon activation, HSCs loose the expression of quiescent markers like neurotrimin and plexin C1 [5], they express high levels of alpha smooth muscle actin (α-SMA), produce large amounts of fibrillar collagens and gain migratory and contractile properties [6,7].”
BackgroundNi, X., Li, X., Wang, Q., & Hua, J. (2020) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-020-00777-7 · Cited by 58
Lakner, A. M. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i40.5047 · Cited by 49
Amplified Inhibition of Stellate Cell Activation Pathways by PPAR-γ, RAR and RXR Agonists
Sharvit, E., Abramovitch, S., Reif, S., & Bruck, R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076541 · Cited by 44
van der Veen, J. N., Lingrell, S., Gao, X., Quiroga, A. D., Takawale, A. R., Armstrong, E. A., Yager, J. Y., Kassiri, Z., Lehner, R. S., Vance, D. E., et al. (2016) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00243.2015 · Cited by 55
Liver fibrogenesis and metabolic factors
Anty, R., & Lemoine, M. (2011) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/s2210-7401(11)70003-1 · Cited by 52
Molecular Cues Guiding Matrix Stiffness in Liver Fibrosis
Saneyasu, T., Akhtar, R., & Sakai, T. (2016) · BioMed Research International · doi:10.1155/2016/2646212 · Cited by 52
“LOX knockout mouse shows perinatal death caused by developmental abnormalities in various tissues such as diaphragm, heart, lung, skin, and vascular tissues [74–76], demonstrating that LOX is essential for normal embryonic development.”
BackgroundTranscriptional regulation of stellate cell activation
Friedman, S. L. (2006) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2006.04585.x · Cited by 47
Tang, Y. (2014) · Digestive Diseases and Sciences · doi:10.1007/s10620-014-3487-6 · Cited by 46
Resolving fibrosis in the diseased liver: Translating the scientific promise to the clinic
Muddu, A. K., Guha, I. N., Elsharkawy, A. M., & Mann, D. A. (2006) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2006.10.006 · Cited by 55
Nuclear receptors in liver fibrosis
Königshofer, P., Brusilovskaya, K., Petrenko, O., Hofer, B. S., Schwabl, P., Trauner, M., & Reiberger, T. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2021.166235 · Cited by 45
Singular effects of PPAR agonists on nonalcoholic fatty liver disease of diet-induced obese mice
Barbosa‐da‐Silva, S., Souza‐Mello, V., Magliano, D. C., Marinho, T. D. S., Águila, M. B., & Mandarim‐de‐Lacerda, C. A. (2015) · Life Sciences · doi:10.1016/j.lfs.2015.02.003 · Cited by 46
Liu, X., Wang, L., Tan, S., Chen, Z., Wu, B., & Wu, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.814871 · Cited by 54
Ho, T., Chen, S., Shih, S., Wu, J.-Y., Han, W.-H., Cheng, H.-C., Yang, S.-L., & Tsao, Y. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.091085 · Cited by 45
Cao, H., Li, S., Xie, R., Xu, N., Qian, Y., Chen, H., Hu, Q.-Y., Quan, Y., Yu, Z., Liu, J., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00187 · Cited by 47
Lu, L., Wang, J., Lü, H., Zhang, G., Liu, Y., Wang, J., Zhang, Y., Shang, H., Ji, H. L., Chen, X., et al. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.08.012 · Cited by 44
Self-citationEpigenetics in Liver Fibrosis: Could HDACs be a Therapeutic Target?
Claveria-Cabello, A., Colyn, L., Arechederra, M., Urman, J. M., Berasain, C., Avila, M. A., & Fernandez-Barrena, M. G. (2020) · Cells · doi:10.3390/cells9102321 · Cited by 43
“Earlier studies showed that PPARγ expression must be silenced in HSC in order to become activated HSC and develop the myofibroblastic phenotype [55].”
BackgroundAttia, Y. M., Elalkamy, E. F., Hammam, O. A., Mahmoud, S. S., & El-Khatib, A. S. (2013) · Parasites & Vectors · doi:10.1186/1756-3305-6-199 · Cited by 43
Hepatic Fibrosis and Cirrhosis
Rockey, D. C. (2015) · Wiley eBooks · doi:10.1002/9781118512074.ch105 · Cited by 41
Gut Microbiota‐Butyrate‐PPARγ Axis Modulates Adipose Regulatory T Cell Population
Chen, B., Guan, L., Wu, C., Gong, Y., Wu, L., Zhang, M., Cao, Z., Chen, Y., Yang, C., Wang, B., et al. (2025) · Advanced Science · doi:10.1002/advs.202411086 · Cited by 52
Self-citationTsukamoto, H. (2005) · The Keio Journal of Medicine · doi:10.2302/kjm.54.190 · Cited by 42
Self-citationChoudhary, R., Li, H. Y., Winn, R. A., Sorenson, A. L., Weiser‐Evans, M. C. M., & Nemenoff, R. A. (2010) · Neoplasia · doi:10.1593/neo.91638 · Cited by 42
“In NSCLC, activation of PPARγ can inhibit growth of NSCLC cells in vitro and in xenograft models [23–25].”
BackgroundPan, H., Reifsnyder, P. C., Vance, D. E., Xiao, Q., & Leiter, E. H. (2005) · Diabetes · doi:10.2337/diabetes.54.6.1854 · Cited by 39
Ameliorative effect of curcumin on hepatotoxicity induced by chloroquine phosphate
Dattani, J. J., Rajput, D. K., Moid, N., Highland, H. N., George, L.-B., & Desai, K. R. (2010) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2010.04.001 · Cited by 40
Alteration of AP-endonuclease1 expression in curcumin-treated fibrotic rats
Bassiouny, A. R., Zaky, A., Fawky, F., & Kandeel, K. (2011) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31521-2 · Cited by 39
Morphogens and hepatic stellate cell fate regulation in chronic liver disease
Tsukamoto, H., Zhu, N., Wang, J., Asahina, K., & Machida, K. (2012) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2011.07022.x · Cited by 37
Self-citationWhiteside, C. I., Wang, H., Xia, L., Munk, S., Goldberg, H. J., & Fantus, I. G. (2009) · Experimental Diabetes Research · doi:10.1155/2009/910783 · Cited by 37
Current Therapeutical Approaches Targeting Lipid Metabolism in NAFLD
Vitulo, M., Gnodi, E., Rosini, G., Meneveri, R., Giovannoni, R., & Barisani, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612748 · Cited by 37
“In activated macrophages, increased PPARγ expression can reduce the secretion of cytokines such as IL-1β and TNF-α and this, in turn, can prevent the switch from quiescent to activated hepatic stellate cells [49,194].”
BackgroundTsai, T., Shih, S., Ho, T., Ma, H., Liu, M., Chen, S., & Tsao, Y. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095443 · Cited by 36
“PPARc is highly expressed in quiescent HSCs in the normal liver and its expression decreases dramatically in activated HSCs both in vitro [21,22] and in vivo [22,23].”
BackgroundJin, H., Terai, S., & Sakaida, I. (2007) · Journal of Gastroenterology · doi:10.1007/s00535-007-2020-5 · Cited by 37
Fat paradox of steatohepatitis
Tsukamoto, H., She, H., Hazra, S., Cheng, J. H., & Wang, J. (2008) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2007.05294.x · Cited by 38
Self-citationPrevention and treatment of Schistosoma mansoni-induced liver fibrosis in mice
El‐Agamy, D. S., Shebl, A. M., & Said, S. A. (2011) · Inflammopharmacology · doi:10.1007/s10787-011-0092-6 · Cited by 37
“Although there is direct molecular evidence for a key role for PPAR-c as a regulator of fibrogenesis (Hazra et al. 2004) PPAR-c agonist can activate the expression of PPAR-c, inhibit the expression of a-SMA and collagen I in activated HSCs; the proliferation of activated HSCs and induce apoptosis of activated HSCs (Gu…”
BackgroundDocosahexaenoic acid attenuates carbon tetrachloride-induced hepatic fibrosis in rats
He, J., Bai, K., Hong, B., Zhang, F., & Zheng, S. (2017) · International Immunopharmacology · doi:10.1016/j.intimp.2017.09.013 · Cited by 38
Zhou, Y., Zhou, J., Sun, B., Xu, W. G., Zhong, M., Li, Y., He, C., Chen, Y., Wang, X., Jones, P. M., et al. (2020) · International Journal of Biological Sciences · doi:10.7150/ijbs.37861 · Cited by 36
Hepatic stellate cell line modulates lipogenic transcription factors
Guimarães, E. L. M., Franceschi, M. F. S., Andrade, C. M. B., Guaragna, R. M. V. D. C., Borojević, R., Margis, R., Bernard, E. A., & Guma, F. T. C. R. (2007) · Liver International · doi:10.1111/j.1478-3231.2007.01578.x · Cited by 39
Rosiglitazone attenuates suppression of RXRα-dependent gene expression in inflamed liver
Ghose, R., Mulder, J., von Furstenberg, R. J., Thevananther, S., Kuipers, F., & Karpen, S. J. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2006.09.008 · Cited by 36
“Another possible role for Rosi and PPARc involves direct association with other nuclear regulators, as has been reported whereby PPARc associates with JunD in hepatic stellate cells to decrease JunD binding to the AP1 site [32].”
BackgroundHuang, M.-Y., Chung, C., Chang, W., Lin, C., Chen, K., Hsieh, T., Chien, W., & Lin, H. (2017) · PubMed · Cited by 35
Cheng, H.-C., Ho, T., Chen, S., Lai, H.-Y., Hong, K.-F., & Tsao, Y. (2008) · PubMed Central · Cited by 32
Wnt Pathway Stabilizes MeCP2 Protein to Repress PPAR-γ in Activation of Hepatic Stellate Cells
Kweon, S.-M., Chi, F., Higashiyama, R., Lai, K. K. Y., & Tsukamoto, H. (2016) · PLoS ONE · doi:10.1371/journal.pone.0156111 · Cited by 32
Self-citationZhang, H., Yan, X., Guo, X.-X., Shi, M.-J., Lu, Y.-Y., Zhou, Q., Chen, Q., Hu, Y., Xu, L., Huang, S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.23262 · Cited by 32
Grouix, B., Sarra‐Bournet, F., Leduc, M., Simard, J.-C., Hince, K., Geerts, L., Blais, A., Gervais, L., Laverdure, A., Felton, A., et al. (2018) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.250068 · Cited by 32
“PPARg downregulation is a well known marker of stellate cell activation (Hazra et al., 2004).”
BackgroundIso-alpha acids from hops (Humulus lupulus) inhibit hepatic steatosis, inflammation, and fibrosis
Mahli, A., Koch, A., Fresse, K., Schiergens, T. S., Thasler, W. E., Schönberger, C., Bergheim, I., Bosserhoff, A., & Hellerbrand, C. (2018) · Laboratory Investigation · doi:10.1038/s41374-018-0112-x · Cited by 33
Zhang, J., Powell, C. A., Kay, M., Sonkar, R., Meruvu, S., & Choudhury, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041822 · Cited by 35
Lin, C., Adhikary, P., & Cheng, K. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.04.008 · Cited by 35
Nishino, A., Maoka, T., & Yasui, H. (2021) · Antioxidants · doi:10.3390/antiox11010043 · Cited by 32
“PPARγ is highly expressed in hepatic stellate cells under normal liver conditions; however, its function is diminished in activated hepatic stellate cells along with their expression levels, while PPARγ ligands have also been reported to have an inhibitory effect on activated hepatic stellate cells [50].”
BackgroundHuang, C., Ma, T., Meng, X., Lv, X., Zhang, L., Wang, J., & Li, J. (2010) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.62.02.0010 · Cited by 34
Self-citationWang, S., Tang, C. W., Zhao, H., Shen, P., Lin, C., Zhu, Y., & Han, D. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.656115 · Cited by 35
Bian, E., Zhao, B., Huang, C. Z., Wang, H., Meng, X., Wu, B., Ma, T., Zhang, L., Lv, X., & Li, J. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2013.05.017 · Cited by 34
Mohamed, I., Sarhan, N. R., Eladl, M. A., El‐Remessy, A. B., & El‐Sherbiny, M. (2018) · Acta Histochemica · doi:10.1016/j.acthis.2018.02.006 · Cited by 29
Curcumin adds spice to the debate: lipid metabolism in liver disease
Graham, A. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00335.x · Cited by 28
“This paradox was highlighted by Tsukamoto et al. (Miyahara et al., 2000; Hazra et al., 2004; Tsukamoto, 2005; Tsukamoto et al., 2006), who observed that trans-differentiation of HSC to MF essentially models adipocytes-pre-adipocytic fibroblast de-differentiation: both quiescent HSC and adipocytes…”
BackgroundPharmacological modulation of ferroptosis as a therapeutic target for liver fibrosis
Li, L., & Zhu, Z. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1071844 · Cited by 30
“, 2007), which are essential for maintaining the quiescent HSCs phenotype (Hazra et al., 2004; She et al., 2005).”
BackgroundHsu, W.-H., Lee, B., Hsu, Y.-W., & Pan, T. (2013) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf402082g · Cited by 28
Zhou, Z., Zhang, R., Li, X., Zhang, W., Zhan, Y., Lang, Z., Tao, Q., Yu, J., Yu, S., Yu, Z., et al. (2024) · Communications Biology · doi:10.1038/s42003-024-05797-3 · Cited by 30
Curcumin affects β-catenin pathway in hepatic stellate cell in vitro and in vivo
Cui, L., Jia, X., Zhou, Q., Zhai, X., Zhou, Y., & Zhu, H. (2014) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12283 · Cited by 28
Evolving Insights on Metabolism, Autophagy, and Epigenetics in Liver Myofibroblasts
Nwosu, Z. C., Alborzinia, H., Wölfl, S., Dooley, S., & Liu, Y. (2016) · Frontiers in Physiology · doi:10.3389/fphys.2016.00191 · Cited by 27
“For instance, transcriptional silencing of PPARγ, which occurs during HSC activation (Hazra et al., 2004), has been attributed to methylation based epigenetic control (Mann et al., 2007; Yang et al., 2012).”
BackgroundXing, X., Chen, S., Li, L., Cao, Y., Chen, L., Wang, X., & Zhu, Z. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00525 · Cited by 29
“Peroxisome proliferator activator receptor gamma was proposed as a crucial factor for the inhibition of HSCs activation (Hazra et al., 2004; Tsukamoto, 2005; Yang et al., 2006).”
BackgroundCao, X., Liu, W., Ai, Q., Li, X., Li, J., Fang, W. Y., Huang, Y., Wang, C., & Jiang, G. (2020) · Aquaculture Nutrition · doi:10.1111/anu.13097 · Cited by 26
Evidence-Based Efficacy of Kampo Formulas in a Model of Non Alcoholic Fatty Liver
Fujimoto, M., Tsuneyama, K., Kainuma, M., SEKIYA, N., Goto, H., Takano, Y., TERASAWA, K., Selmi, C. F., Gershwin, M. E., & Shimada, Y. (2008) · Experimental Biology and Medicine · doi:10.3181/0707-rm-207 · Cited by 26
Burrage, P. S., Schmucker, A. C., Ren, Y., Sporn, M. B., & Brinckerhoff, C. (2008) · Arthritis Research & Therapy · doi:10.1186/ar2564 · Cited by 27
“PPAR directly interacts with at least one member of the AP-1 transcription factor family [43], and there are examples of other NHRs directly interacting with the AP-1 transcription factors [44-46].”
BackgroundRetinoic Acid: A New Old Friend of IL-17A in the Immune Pathogeny of Liver Fibrosis
Kartasheva-Ebertz, D., Pol, S., & Lagaye, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.691073 · Cited by 25
Pérez‐Carreón, J. I., Martínez-Pérez, L., Loredo, M. L., Yañez-Maldonado, L., Velasco-Loyden, G., Vidrio, S., Ramírez-Salcedo, J., Hernández‐Luis, F., Velázquez‐Martínez, I., Suárez‐Cuenca, J. A., et al. (2009) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2009.11.005 · Cited by 25
Bruck, R., Weiss, S., Aeed, H., Pines, M., Halpern, Z., & Zvibel, I. (2008) · Digestive Diseases and Sciences · doi:10.1007/s10620-008-0336-5 · Cited by 25
“Transfection of activated HSC with PPARc reversed their activated phenotype and the cells became quiescent, as demonstrated by reduced DNA synthesis, suppression of aSMA and collagen I synthesis and inhibition of junD binding to AP-1 [33].”
Backgroundde Souza, I. C. C., Martins, L. A. M., de Vasconcelos, M., de Oliveira, C. M., Barbé‐Tuana, F. M., Andrade, C. M. B., Pettenuzzo, L. F., Borojević, R., Margis, R., Guaragna, R. M. V. D. C., et al. (2015) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25181 · Cited by 27
“…PPARgligands inhibits cell proliferation and the expression of both a-SMA type I collagen and monocyte chemotactic protein 1, a potent chemokine secreted by activated HSC that recruits and activates monocytes and T-lymphocytes [Miyahara et al., 2000; Eng and Friedman, 2001; Hazra et al., 2004].”
BackgroundNecela, B. M., Su, W., & Thompson, E. A. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m804481200 · Cited by 27
Miyoshi, M., Kakinuma, S., Kamiya, A., Tsunoda, T., Tsuchiya, J., Sato, A., Kaneko, S., Nitta, S., Kawai‐Kitahata, F., Murakawa, M., et al. (2019) · Scientific Reports · doi:10.1038/s41598-018-37430-9 · Cited by 24
EZH2 as a Potential Target for NAFLD Therapy
Lim, H. J., & Kim, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228617 · Cited by 25
Albumin mediates PPAR-γ or C/EBP-α-induced phenotypic changes in pancreatic stellate cells
Kim, N., Choi, S., Lim, C., Lee, H. S., & Oh, J. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.11.112 · Cited by 26
Metabolic injury of hepatocytes promotes progression of NAFLD and AALD
Carvalho-Gontijo, R., Han, C., Zhang, L., Zhang, V., Hosseini, M., Mekeel, K., Schnabl, B., Loomba, R., Karin, M., Brenner, D. A., et al. (2022) · Seminars in Liver Disease · doi:10.1055/s-0042-1755316 · Cited by 23
Emerging physiological and pathological roles of MeCP2 in non-neurological systems
Wang, J., Xiao, Y., Liu, C., Huang, Y., Petersen, R. B., Zheng, L., & Huang, K. (2021) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2021.108768 · Cited by 23
Self-citationSalas, S. S., Arroyave-Ospina, J. C., Zhang, M., Damba, T., Buist‐Homan, M., Muñoz‐Ortega, M. H., Ventura‐Juárez, J., & Moshage, H. J. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111617 · Cited by 23
Coyle, A. T., & Kinsella, B. T. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.01.011 · Cited by 26
“PPAR(grgamma) agonists are known to reduce AP-1 activation in several experimental systems, by mechanisms that involve direct interaction of PPAR(grgamma) with c-Jun [19] or JunD [45], inhibition of c-Fos expression [57] and the competitive binding of activated PPAR(grgamma) to a composite PPRE/AP-1 site [58].”
Background
Metadata
- Authors
- Hazra, S., Xiong, S., Wang, J., Rippe, R. A., Krishna, V., Chatterjee, K., & Tsukamoto, H.
- Affiliations
- University of Southern California (US)
- University of North Carolina at Chapel Hill (US)
- University of Cambridge (GB)
- Corresponding author
- Tsukamoto, Hidekazu
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2004-03
- Volume
- 279
- Issue
- 12
- Pages
- 11392-11401
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2091296342
- Cited by
- 320
- References
- 38
- Citations by year
- 2026: 12 · 2025: 9 · 2024: 8 · 2023: 12 · 2022: 9 · 2021: 17 · 2020: 15 · 2019: 11 · 2018: 13 · 2017: 17 · 2016: 16 · 2015: 19 · 2014: 11 · 2013: 13 · 2012: 10
- FWCI
- 12.78
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6057 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- U.S. Department of Veterans Affairs (P50AA11999)
- University of Southern California (P30DK48522)
- National Institutes of Health
- National Institute on Alcohol Abuse and Alcoholism (R24 AA12885, P50-AA11999, R37AA006603, R37-AA-06603, R24AA012885, P50AA011999)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30-DK-48522, P30DK048522)
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Keywords
- PPARγ, hepatic stellate cells, liver fibrosis, myofibroblast transdifferentiation, JunD, AP-1 transcription factor, PPARγ ligands, retinyl palmitate, alpha-smooth muscle actin, type I collagen, TGF-β1, adenoviral gene transfer
- MeSH terms
- Retinyl Esters, Animals, Binding Sites, Cell Division, Cells, Cultured, Diterpenes, Liver, Male, Phenotype, Transcription Factors, Vitamin A, Polymerase Chain Reaction, Rats, Wistar, DNA, Complementary, Receptors, Cytoplasmic and Nuclear, Transcription Factor AP-1, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.